Atossa Therapeutics, Inc.

ATOS

Healthcare|Biotechnology|US

$2.12

+0.10 (+4.95%)

DCF Value

$4.35

Tangible Book / Share

$3.01

Cash / Share

$2.93

Next Earnings Report

Nov 11, 2026

EPS est. -$0.86

Financing Filings (last 12 months)

Shelf registrations / offering prospectuses — latest Jun 12, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Nov 2026

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

NCT05607004

Recent Press Releases

Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today

Oct 19, 2026 · PRNewsWire

Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value

Oct 9, 2026 · PRNewsWire

Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher

Sep 29, 2026 · PRNewsWire

Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging

Sep 24, 2026 · PRNewsWire

SEC Filings (56)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Oct 9, 2026	8-K	Material event	Document Index
Sep 29, 2026	8-K	Material event	Document Index
Sep 18, 2026	8-K	Material event	Document Index
Aug 7, 2026	8-K	Material event	Document Index
Aug 7, 2026	10-Q	Quarterly report	Document Index
Jun 12, 2026	424B5	Offering prospectus	Document Index
Jun 11, 2026	8-K	Material event	Document Index
May 8, 2026	8-K	Material event	Document Index
May 8, 2026	10-Q	Quarterly report	Document Index
May 8, 2026	8-K	Material event	Document Index
Apr 16, 2026	8-K	Material event	Document Index
Mar 30, 2026	ARS	Annual report to holders	Document Index
Mar 30, 2026	DEF 14A	Proxy / shareholder vote	Document Index
Mar 25, 2026	10-K	Annual report	Document Index
Mar 25, 2026	8-K	Material event	Document Index
Mar 20, 2026	PRE 14A	Proxy / shareholder vote	Document Index
Feb 20, 2026	8-K	Material event	Document Index
Feb 20, 2026	424B5	Offering prospectus	Document Index
Feb 20, 2026	424B3	Offering prospectus	Document Index
Feb 17, 2026	8-K	Material event	Document Index
Feb 11, 2026	8-K	Material event	Document Index
Jan 26, 2026	8-K	Material event	Document Index
Jan 9, 2026	8-K	Material event	Document Index
Jan 6, 2026	8-K	Material event	Document Index
Dec 22, 2025	DEF 14A	Proxy / shareholder vote	Document Index
Dec 12, 2025	PRE 14A	Proxy / shareholder vote	Document Index
Dec 4, 2025	8-K	Material event	Document Index
Nov 12, 2025	10-Q	Quarterly report	Document Index
Nov 12, 2025	8-K	Material event	Document Index
Oct 14, 2025	8-K	Material event	Document Index
Sep 26, 2025	8-K	Material event	Document Index
Sep 8, 2025	8-K	Material event	Document Index
Aug 21, 2025	8-K	Material event	Document Index
Aug 12, 2025	10-Q	Quarterly report	Document Index
Aug 12, 2025	8-K	Material event	Document Index
Jul 29, 2025	SC 13G/A	Passive 5%+ stake	Document Index
Jul 16, 2025	SC 13G/A	Passive 5%+ stake	Document Index
May 13, 2025	10-Q	Quarterly report	Document Index
May 13, 2025	8-K	Material event	Document Index
May 12, 2025	8-K	Material event	Document Index